PDF Archive search engine
Last database update: 17 May at 12:28 - Around 76000 files indexed.
Prize for Biotechnology Innovation In 2014 in honor of the 10th Anniversary of the Center for Biotechnology and Interdisciplinary Studies (CBIS), Rensselaer partnered with the Seymour Fox Memorial Foundation to establish The Seymour Fox Lecture and Prize for Biotechnology Innovation.
ARMENIA GEORGIA THE UNIVERSITY OF TENNESSEE KNOXVILLE The INTERNATIONAL WORKSHOP On BIOLOGY AND BIOTECHNOLOGY OF THERMOPHILIC MICROORGANISMS CONTENTS Preface 4 Preamble 10 Organizing Committee 12 Executive Summary 8 List of Authors 12 Workshop Participants 13 WORKSHOP IN GEORGIA Introduction 14 Section 1 Collection of microorganisms 16 Section 5 Potential for commercialization 32 Section 2 Microbial diversity 20 Section 6 Student education and investment in research/ biotechnology 36 Section 3 Sequence data and computational analysis 24 Section 7 Cultural component of the visit 40 Section 4 Thermophilic field-site 28 Overall Panel recommendations for Georgia 42 WORKSHOP IN ARMENIA Introduction 44 Section 1 Collection of microorganisms 46 Section 2 Microbial diversity 50 Section 5 Potential for commercialization 62 Section 6 Biomedical research 66 Section 3 Sequence data and computational analysis 54 Section 7 Student education and investment in research/ biotechnology 70 Section 4 Thermophilic field-site 58 Section 8 Cultural component of the visit 74 Overall Panel recommendations for Armenia 76 Conclusions and Recommendations 78 P.
PhD student in Chemical Engineering and Biotechnology, University of Chile.
You will gain knowledge in law and ICT, but also explore questions and issues surrounding controversial and fascinating technological developments in biotechnology, nanotechnology, and neuroscience.
Here we are speaking of biological reproduction as facilitated by biotechnology, one of the most capital-intensive industries on the planet.
Torts, Education Law, Legal Ethics, Social Policy, Health Regulations, Health Law Policy, Reproductive Medicine, Biotechnology &
30206052 William Heyman Krill Knudeteori og DNA December 2013 Abstract This paper examines the applications of knot theory to biotechnology.
4 August 2015 FOR IMMEDIATE RELEASE CONTACT: Zack Struver +1 (202) 3322670 firstname.lastname@example.org Knowledge Ecology International Leaks TPP Text on Intellectual Property Tuesday, August 4th, 2015 Washington, DC — Today, August 4, 2015, Knowledge Ecology International (KEI) released text from three sections of the 95page secret negotiating text on the Intellectual Property Chapter being used in the TransPacific Partnership Agreement (TPP, sometimes referred to as TPPA) trade negotiations. The negotiating text is dated May 11, 2015, and reflects the state of the text right before the Maui rounds of the negotiation, which ended Friday, July 31, 2015. Released this morning is text from the following sections of the IP Chapter: ● All of Section B on Cooperation. (Pages 8 to 10 of the IP Chapter) ● All of Section E on “Patents / Undisclosed Test or Other Data / Traditional Knowledge.” (Pages 29 to 53 of the IP Chapter) ● Articles 1 through 11 from Section H on enforcement. (Pages 67 through 89 of the IP Chapter) We hope to release the remaining sections (A, C, D, F, G, and the rest of H) later today and Wednesday. The text will be placed on this web page: http://keionline.org/tpp/11may2015iptext The text released this morning is most relevant to issues related to pharmaceuticals, especially rules on biologics and new chemicals. Later today or tomorrow, KEI will release sections of the text relevant to copyright and trademarks. KEI will publish a more detailed analysis of the text later. James Love, Director of Knowledge Ecology International, released the following statement this morning: “KEI is publishing the consolidated text for the TPP IP Chapter from May 11, 2015, in order to enable the public to understand, analyze, and influence the rules that have been proposed for intellectual property in this important trade negotiation. Over 600 corporate advisors already have access to this text, and this leak, at least temporarily, levels the field somewhat (there will be a new text coming out of last week’s talks in Maui). The May 11, 2015, text includes country positions, and reveals extensive disagreements among parties, as well as the isolation of the United States as the country that continues to be the most aggressive supporter of expanded intellectual property rights for drug companies, publishers and other companies. The proposals contained in the TPP will harm consumers and in some cases block innovation. In countless ways, the Obama Administration has sought to expand and extend drug monopolies and raise drug prices. The astonishing collection of proposals page 1 of 4 pandering to big drug companies make more difficult the task of ensuring access to drugs for the treatment of cancer and other diseases and conditions. The widely reported dispute over the number of years of protection for biologic drug test data is only one of dozens of measures that significantly expand the power of big drug companies to charge high prices. Taken together these provisions will take the public down a road of more and more rationing of medicines, and less and less equality of access. It could have and still can be different. Rather than focusing on more intellectual property rights for drug companies, and a deathinducing spiral of higher prices and access barriers, the trade agreement could seek new norms to expand the funding of medical R&D as a public good, an area where the United States has an admirable track record, such as the public funding of research at the NIH and other federal agencies. Many people reading the provisions released today will appreciate how misguided and wrong are the USTR’s values and negotiating objectives.” James Love, Director, KEI, August 4, 2015 For more information and perspectives, we are also attaching the names and contact information for several persons who can comment on the text released this morning, including health and consumer group NGOs, academics, and industry experts. Health and consumer group NGOs Knowledge Ecology International ● ● ● James Love, Director, +1.202.361.3040, email@example.com Andrew S. Goldman, Counsel for Policy & Legal Affairs, +1.202.332.2670, firstname.lastname@example.org Thiru Balasubramaniam, Geneva Representative, email@example.com, +41 22 791 6727 Public Citizen ● ● Peter Maybarduk, Director, +1.202.588.7755, firstname.lastname@example.org Burcu Kilic, Research Director, +1.202.588.7792, email@example.com Doctors Without Borders/Médecins Sans Frontières ● Judit Rius Sanjuan, U.S. Manager & Legal Policy Adviser, Access Campaign, T: +1.212.655.3762, M: +1.917.331.9077, Judit.Rius@newyork.msf.org Academics Professor Susan K. Sell Elliott School of International Affairs George Washington University T: (202) 9944896 firstname.lastname@example.org Professor Kevin Outterson Boston University School of Law email@example.com Dr. Deborah Gleeson Department of Public Health La Trobe University Melbourne, Australia T: +61 3 9479 3262 M: +61 423 209029 firstname.lastname@example.org Professor Margot Kaminski page 2 of 4 Moritz College of Law Ohio State University email@example.com Professor Brook K. Baker Program on Human Rights and the Global Economy Northeastern University School of Law T: (617) 373=3217 M: (617) 2590760 firstname.lastname@example.org Dr. Ruth Lopert Department of Public Health George Washington University (202) 4157726 email@example.com Pharmaceutical and biotechnology industry experts who are familiar with the TPP IP Chapter Joseph Damond Senior Vice President, International Affairs Biotechnology Industry Organization (BIO) jDamond@bio.org Members of USTR’s Industry Trade Advisory Committees (ITAC) ITAC 15: Industry Trade Advisory Committee on Intellectual Property Rights Gregg H. Alton, Esq. Executive Vice President, Corporate and Medical Affairs, Secretary and Chief Compliance Officer Gilead Sciences, Inc. Paul A. Coletti Associate Patent Counsel Johnson & Johnson Erik H. Iverson, Esq. President, Business and Operations Infectious Disease Research Institute Mr. Richard H. Kjeldgaard Consultant Representing Pharmaceutical Research and Manufacturers of America Jeffrey P. Kushan, Esq. Sidley Austin Representing Biotechnology Industry Organization Jonathan L. Marks, Esq. Vice President, International Affairs Generic Pharmaceuticals Association ITAC 3: Industry Trade Advisory Committee On Chemicals, Pharmaceuticals, Health/Science Products And Services Ms. Tiffany McCullen Atwell Director, International Government Affairs DuPont Government Marketing and Government Affairs E.I. du Pont de Nemours and Company page 3 of 4 Mr. Harrison C. Cook Vice President, International Government Affairs Eli Lilly and Company Mr. Ralph F. Ives Executive Vice President, Global Strategy and Analysis AdvaMed: Advanced Medical Technology Association Mr. Maurice J. Kerins President Airmed Biotech, Inc. Douglas T. Nelson, Esq. Senior Advisor for Trade, Intellectual Property and Strategic Affairs CropLife America Mr. Paul A. Neureiter Executive Director, Government Affairs Amgen Inc. Mr. James R. Plante Founder and Chief Executive Officer Pathway Genomics Ms. Lisa M. Schroeter Global Director, Trade and Investment Policy The Dow Chemical Company ### page 4 of 4
Bo Yu Deputy Director CAS-TWAS Centre of Excellence for Biotechnology-China Dr.
Optional Information My professional career has focused on biotechnology.
firstname.lastname@example.org -------------------------------------------------- Major fields of interest Pharmacology, biochemistry, toxicology, cell biology, biotechnology Education 2012 to Present:
She is a determined and hardworking freshman, Giving Back majoring in biology with a concentration in biotechnology.
35 Veridian Biotechnology Limited ..................................................................................................................... 36 Viewider Limited ..............................................................................................................................................
Services G352010S Biotechnology G352020S Pharmaceuticals G352030S Life Sciences Tools &
Entertainment $363M 39 Biotechnology $277M 27 Industrial/Energy $229M 18 $2.50 Medical Devices and Equipment $201M 20 Computers and Peripherals $177M 4 Semiconductors $90M 7 $2.00 Telecommunications $38M 5 Q4-12 Q1-13 0.00% Avg.
Between 2003 and 2009, Fatiha Sadallah held a scientific officer position at the EC-DG-RTD, Directorate F, Biotechnology for Health Unit.
IDENTIFICATION OF CHEMICAL CONSTITUENTS IN STONE DAMMAR EXTRACTS AND THEIR POTENCIES AS ANTIBACTERIAL AGENTS Noryawati Mulyono School of Biology, Faculty of Biotechnology, Atma Jaya Catholic University, Jakarta 12930 Indonesia Email email@example.com ABSTRACT Stone dammar, resin obtained from Shorea eximia, grows well in Kalimantan, Sumatra and Sulawesi.